Gene · 2829
Papers1,709
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 1,709
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Protein-O-fucosylation of coreceptors may be required for Nodal signaling in Xenopus. | Mol Cells | 2025 | 40043779 | PubTator, text mining | PubMed |
| Cecelia: a multifunctional image analysis toolbox for decoding spatial cellular interactions and behaviour. | Nat Commun | 2025 | 39994207 | PubTator, text mining | PubMed |
| TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer. | Cancer Immunol Res | 2025 | 39932226 | PubTator, text mining | PubMed |
| The XCL1-XCR1 axis supports intestinal tissue residency and antitumor immunity. | J Exp Med | 2025 | 39841133 | PubTator, text mining | PubMed |
| The multifaceted role of XCL1 in health and disease. | Protein Sci | 2025 | 39840812 | PubTator, text mining | PubMed |
| Optimal chemokine receptors for enhancing immune cell trafficking in adoptive cell therapy. | Immunol Res | 2025 | 39815137 | PubTator, text mining | PubMed |
| GIMAP1 interacts with TMX1 to improve lung adenocarcinoma prognosis by influencing tumor immune microenvironment. | Biochim Biophys Acta Mol Basis Dis | 2025 | 39805394 | PubTator, text mining | PubMed |
| RUNX2 Phase Separation Mediates Long-Range Regulation Between Osteoporosis-Susceptibility Variant and XCR1 to Promote Osteoblast Differentiation. | Adv Sci (Weinh) | 2025 | 39704037 | PubTator, text mining | PubMed |
| Multimodal delineation of a layer of effector function among exhausted CD8 T cells in tumors. | bioRxiv | 2025 | 37808790 | PubTator, text mining | PubMed |
| Bioinformatics analysis identifies WNK1 gene as a potential biomarker for cholangiocarcinoma diagnosis and immune infiltration. | J Genet Eng Biotechnol | 2024 | 39674642 | PubTator, text mining | PubMed |
| Molecular basis for chemokine recognition and activation of XCR1. | Proc Natl Acad Sci U S A | 2024 | 39565315 | PubTator, text mining | PubMed |
| Type I interferon signaling in dendritic cells limits direct antigen presentation and CD8+ T cell responses against an arthritogenic alphavirus. | mBio | 2024 | 39535221 | PubTator, text mining | PubMed |
| Five-gene prognostic model based on autophagy-dependent cell death for predicting prognosis in lung adenocarcinoma. | Sci Rep | 2024 | 39488588 | PubTator, text mining | PubMed |
| Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance. | Sci Adv | 2024 | 39413183 | PubTator, text mining | PubMed |
| Integrating Bulk and Single-Cell RNA-Seq Data to Identify Prognostic Features Related to Activated Dendritic Cells in Clear-Cell Renal-Cell Carcinoma. | Int J Mol Sci | 2024 | 39273185 | PubTator, text mining | PubMed |
| In vivo dendritic cell reprogramming for cancer immunotherapy. | Science | 2024 | 39236156 | PubTator, text mining | PubMed |
| CD4+ T cells reactive to a hybrid peptide from insulin-chromogranin A adopt a distinct effector fate and are pathogenic in autoimmune diabetes. | Immunity | 2024 | 39214091 | PubTator, text mining | PubMed |
| Genome-scale CRISPR-Cas9 screening in stem cells: theories, applications and challenges. | Stem Cell Res Ther | 2024 | 39026343 | PubTator, text mining | PubMed |
| Corrigendum: Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies. | Front Immunol | 2024 | 38979418 | PubTator, text mining | PubMed |
| Imbalance of programmed cell death patterns mediated by dendritic cell subsets in systemic lupus erythematosus and lupus nephritis. | Zhong Nan Da Xue Xue Bao Yi Xue Ban | 2024 | 38970507 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2829/papers?page=4